- Arthur E. FrankelProfessor of Medicin, Scott and White Hospital, 2401 South 31st Street, Temple, Texas 76508Interests: 215 publications, 20 grants, Editor of Frontiers in Bioscience, Molecular Cancer Therapeutics, Clinical Cancer Research, Clinical Pharmacology:Advances and ApplicationsSpecial Issues and Topics in IMR Press journalsSpecial Issue in Clinical antibody drug conjugates
Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 500 USD. Submitted manuscripts should be well formatted in good English.
- ReviewInotuzumab ozogamicin in the treatment of acute lymphoblastic leukemiaNitin Jain, Susan O'Brien, Deborah Thomas, Hagop KantarjianFront. Biosci. (Elite Ed) 2014, 6(1), 40–45; https://doi.org/10.2741/E688(This article belongs to the Special Issue Clinical antibody drug conjugates)48Downloads5Citations51Views